State of New Jersey Common Pension Fund D Buys 8,884 Shares of Glaukos Co. (NYSE:GKOS)

State of New Jersey Common Pension Fund D increased its holdings in shares of Glaukos Co. (NYSE:GKOS) by 26.9% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 41,883 shares of the medical instruments supplier’s stock after purchasing an additional 8,884 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Glaukos were worth $3,329,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Yousif Capital Management LLC raised its stake in shares of Glaukos by 1.9% during the fourth quarter. Yousif Capital Management LLC now owns 24,749 shares of the medical instruments supplier’s stock worth $1,967,000 after buying an additional 465 shares during the last quarter. GAMMA Investing LLC bought a new stake in shares of Glaukos during the fourth quarter worth approximately $55,000. Illinois Municipal Retirement Fund raised its stake in shares of Glaukos by 8.0% during the fourth quarter. Illinois Municipal Retirement Fund now owns 29,336 shares of the medical instruments supplier’s stock worth $2,332,000 after buying an additional 2,166 shares during the last quarter. New York State Common Retirement Fund raised its stake in shares of Glaukos by 0.4% during the fourth quarter. New York State Common Retirement Fund now owns 513,029 shares of the medical instruments supplier’s stock worth $40,781,000 after buying an additional 1,867 shares during the last quarter. Finally, California Public Employees Retirement System raised its stake in shares of Glaukos by 10.2% during the fourth quarter. California Public Employees Retirement System now owns 76,804 shares of the medical instruments supplier’s stock worth $6,105,000 after buying an additional 7,107 shares during the last quarter. 99.04% of the stock is owned by institutional investors.

Glaukos Stock Down 0.6 %

Glaukos stock opened at $99.48 on Friday. The stock has a market capitalization of $4.99 billion, a PE ratio of -35.78 and a beta of 1.08. Glaukos Co. has a twelve month low of $45.38 and a twelve month high of $103.66. The company has a quick ratio of 4.78, a current ratio of 5.34 and a debt-to-equity ratio of 0.77. The company has a 50 day moving average of $92.42 and a 200-day moving average of $81.74.

Glaukos (NYSE:GKOS) last released its quarterly earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.07). The company had revenue of $82.40 million during the quarter, compared to analyst estimates of $81.00 million. Glaukos had a negative net margin of 42.79% and a negative return on equity of 22.67%. The firm’s quarterly revenue was up 15.7% compared to the same quarter last year. During the same quarter last year, the company earned ($0.53) EPS. On average, equities research analysts anticipate that Glaukos Co. will post -2.18 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Gilbert H. Kliman sold 5,000 shares of the stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $88.25, for a total transaction of $441,250.00. Following the completion of the transaction, the director now owns 30,620 shares in the company, valued at $2,702,215. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Marc Stapley sold 6,250 shares of the stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $90.09, for a total transaction of $563,062.50. Following the completion of the transaction, the director now owns 32,360 shares in the company, valued at $2,915,312.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gilbert H. Kliman sold 5,000 shares of the stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $88.25, for a total transaction of $441,250.00. Following the transaction, the director now owns 30,620 shares of the company’s stock, valued at approximately $2,702,215. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 242,357 shares of company stock worth $22,857,372. 6.40% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on GKOS shares. Needham & Company LLC boosted their price target on shares of Glaukos from $105.00 to $108.00 and gave the stock a “buy” rating in a research note on Thursday, February 22nd. StockNews.com downgraded shares of Glaukos from a “hold” rating to a “sell” rating in a research note on Tuesday, February 27th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $110.00 target price on shares of Glaukos in a research note on Wednesday, April 3rd. Truist Financial reaffirmed a “buy” rating and issued a $110.00 target price on shares of Glaukos in a research note on Monday, April 8th. Finally, Citigroup upped their target price on shares of Glaukos from $107.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, March 25th. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, Glaukos currently has an average rating of “Moderate Buy” and an average target price of $99.80.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.